01—Abstract
Summary
Summary of the 10-Q filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. reported strong revenue growth driven by key immunology and neuroscience products in the third quarter of 2025.
Net revenues increased by 9.1% year-over-year to $15.8 billiona, with international markets showing robust performance. Despite this top-line growth, net earnings saw a significant decline to $186 million from $1.6 billion in the prior year period. This decrease is largely attributable to substantial expenses including acquired IPR&D and milestones ($2.7 billion), an increase in interest expense, and a significant unfavorable change in the fair value of contingent consideration liabilities, which amounted to $776 million in the quarter.
The company continues to invest heavily in its pipeline, with R&D expenses remaining a significant cost. Strategic acquisitions and licensing agreements, such as the acquisition of Capstan Therapeutics and the license with Ichnos Glenmark Innovation, highlight AbbVie's commitment to expanding its therapeutic areas, particularly in immunology and neuroscience. While the company faces ongoing legal proceedings and pricing pressures, it maintains a strong liquidity position with substantial cash and equivalents, supported by consistent operating cash flows.
02—Key points
Key Highlights
- Net revenues grew 9.1% to $15.8 billion for Q3 2025, driven by strong performance in Immunology (Skyrizi, Rinvoq) and Neuroscience (Botox Therapeutic, Qulipta).
- Net earnings significantly decreased to $186 million from $1.6 billion year-over-year, primarily due to higher acquired IPR&D and milestone expenses ($2.7 billion) and unfavorable changes in contingent consideration.
- Acquired IPR&D and milestone expenses surged to $2.7 billion in Q3 2025, largely from the acquisitions of Capstan Therapeutics ($1.9 billion) and Ichnos Glenmark Innovation ($700 million).
- Humira's net revenues continued to decline, falling 55.4% year-over-year, reflecting ongoing biosimilar competition.
- The company continues to invest in its pipeline, with R&D expenses increasing 9% to $2.3 billion in Q3 2025.
- AbbVie announced an increase in its quarterly dividend to $1.73 per share, signaling confidence in future performance and commitment to shareholder returns.
- The company's financial position remains strong, with $5.6 billion in cash and equivalents and positive operating cash flows of $13.8 billion for the nine months ended September 30, 2025.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, AbbVie Inc. kept $0.01.
- Revenue$15.78B100.0%
- Cost of revenue−$5.30B33.6%
- Gross profit$10.47B66.4%
- Operating costs−$8.57B54.3%
- Operating income$1.90B12.1%
- Interest, other & tax−$1.72B10.9%
- Net income$186.0M1.2%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed November 4, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $15.78B$14.46B | +9.1% |
| Cost of Revenue | $5.30B$4.21B | +25.9% |
| Gross Profit | $10.47B$10.25B | +2.2% |
| SG&A Expenses | $3.57B$4.21B | −15.1% |
| Operating Expenses | $13.87B$10.63B | +30.5% |
| Operating Income | $1.90B$3.83B | −50.3% |
| Interest Expense | $739.00M$720.00M | +2.6% |
| Net Income | $186.00M$1.56B | −88.1% |
| EPS (Basic) | $0.10$0.88 | −88.6% |
| EPS (Diluted) | $0.10$0.88 | −88.6% |
| Shares Outstanding (Basic) | 1.77B1.77B | 0.0% |
| Shares Outstanding (Diluted) | 1.77B1.77B | 0.0% |
05—Questions
Frequently Asked Questions
What is the primary driver behind the significant drop in net earnings year-over-year?
The substantial decrease in net earnings from $1.6 billion in Q3 2024 to $186 million in Q3 2025 is primarily due to a significant increase in 'Acquired IPR&D and milestones' expenses, which rose to $2.7 billion from $82 million. This was largely driven by upfront payments for strategic acquisitions and licensing deals, such as Capstan Therapeutics and Ichnos Glenmark Innovation. Additionally, unfavorable changes in the fair value of contingent consideration liabilities and increased interest expenses also contributed to the lower net earnings.
How are AbbVie's key growth products performing?
AbbVie's key growth products are showing strong momentum. Skyrizi net revenues increased by 46.8% year-over-year in the third quarter, and Rinvoq net revenues grew by 35.3%. Neuroscience products like Botox Therapeutic (+16.1%) and Qulipta (+64.1%) also demonstrated robust growth, indicating successful market penetration and uptake.
What is the company's strategy regarding research and development and future growth?
AbbVie continues to prioritize R&D, with expenses increasing 9% to $2.3 billion in Q3 2025. The company is focused on expanding its pipeline in immunology, neuroscience, oncology, aesthetics, and eye care. Recent strategic moves include significant investments in acquisitions and licensing agreements to bring innovative therapies and technologies into its portfolio, aiming to diversify its revenue base and secure long-term growth drivers.
What is the outlook for Humira's performance given the biosimilar competition?
Humira's performance continues to be negatively impacted by direct biosimilar competition, with net revenues decreasing by 55.4% year-over-year in the third quarter. This trend is expected to persist as biosimilars gain market share. AbbVie is focused on mitigating this impact through its growth products like Skyrizi and Rinvoq.
06—Continue